LY2459989

LY2459989 is an experimental drug developed for the treatment of opioid addiction. It is a kappa opioid receptor antagonist, which means it blocks the action of kappa opioid receptors in the brain. This action is believed to reduce the symptoms of opioid withdrawal and decrease the desire to use opioids.

Mechanism of Action

LY2459989 works by binding to kappa opioid receptors in the brain and blocking their action. These receptors are involved in the body's response to stress and pain, and are thought to play a role in the development of opioid addiction. By blocking these receptors, LY2459989 may help to reduce the symptoms of opioid withdrawal and decrease the desire to use opioids.

Clinical Trials

LY2459989 has been tested in several clinical trials for its effectiveness in treating opioid addiction. In these trials, it has shown promise in reducing the symptoms of opioid withdrawal and decreasing the desire to use opioids. However, more research is needed to confirm these findings and to determine the optimal dosage and treatment duration.

Side Effects

As with any drug, LY2459989 can cause side effects. These may include nausea, vomiting, and dizziness. It is important for patients to discuss any potential side effects with their healthcare provider before starting treatment with LY2459989.

Future Research

While the results of clinical trials so far are promising, more research is needed to fully understand the potential benefits and risks of LY2459989. Future studies may focus on determining the optimal dosage and treatment duration, as well as exploring the drug's effectiveness in different populations.

See Also

• Opioid addiction
• Kappa opioid receptor
• Clinical trial